Japan Tobacco Inc.

Makoto Shiozaki

Masahiro Yokota

Hiroshi Yamanaka

Noriyoshi Seki

Akira Suma

Katsuya Maeda

Steven Wade Andrews

Hiroyuki Abe

Masahiro Tanaka

Julia Haas

Masato Noguchi

Takashi Inaba

Ellen Ruth Laird

Takayuki Sakai

Eiichi Watanabe

Masafumi Inoue

Taku Ikenogami

Yoshikazu Hori

Satoru Noji

Tomoya Miura

Dai Motoda

Kiyosei Iio

Yosuke Ogoshi

Kazuhito Ueyama

Kazuyuki Sugimoto

Shintaro Hirashima

Takaki Maeba

Yoshinori Hara

Masayuki Kotoku

Shingo Fujioka

Tamotsu Negoro

Kazayuki Hirata

Hiroto Imai

Yuichi Shinozaki

Takafumi Matsuo

Andrew M Fryer

Atushi Sakai

Katsutaka Yasue

Nicole M Littmann

Satoki Doi

Junichiro Tsuruha

Tsuyoshi Adachi

Toru Noguchi

Shingo Obika

Yasunori Hase

Akimi Hori

Kazuyuki Hirata

A compound of Formula [I] or a pharmaceutically acceptable salt thereof: wherein each symbol is defined as in the specification.

Dihydropyrimidin-2-one compounds and medical use thereof

A compound of the following general formula [I]: wherein each symbol has the same meaning as defined herein, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical use of the same in treating organ transplant rejection, graft versus host reaction after transplantation, autoimmune disease, allergic disease and chronic myeloproliferative disease.

Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof

A compound of formula [I-W]: wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

Amide compound and medicinal use thereof

The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

Piperazine compound and use thereof as a HCV polymerase inhibitor

The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein Ris &#x2014;(CH)&#x2014;X&#x2014;(CH)-Aetc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and Ais a substituted Chydrocarbon ring group, etc.; Rand Rare the same or different and each is a hydrogen atom, &#x2014;(CH)&#x2014;X&#x2014;(CH)-A, etc., wherein p and q are the same or different and each is 0 to 6, Xis a single bond, etc. and Ais an optionally substituted Chydrocarbon ring group, etc.; Ris &#x2014;COR, etc., wherein Ris a hydrogen atom, etc.; and Rand Rare the same or different and each is a hydrogen atom, &#x2014;(CH)&#x2014;X&#x2014;(CH)&#x2014;R, etc., wherein m12 and m12 are the same or different and each is 0 to 6, Xis a single bond, etc. and Ris a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.

Cyclopropane compounds and pharmaceutical use thereof

Growing community of inventors

Osaka, Japan

Makoto Shiozaki